Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients
- Conditions
- Covid19
- Interventions
- Drug: Angiotensin-(1-7)Drug: Placebo
- Registration Number
- NCT04570501
- Lead Sponsor
- Stanford University
- Brief Summary
The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and mortality in patients with COVID 19.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Signs and symptoms suggestive of COVID-19 infection including cough or dyspnea
- Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) test β€7 days before randomization
- Currently hospitalized or in an emergency department with planned hospitalization
- Peripheral capillary oxygen saturation (SpO2) β€93% on room air or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) <300 at Screening
- Simultaneous participation in any other clinical study incompatible with this one
- Treatment with an antibody immunotherapy that is not standard of care for COVID-19 within 4 weeks of Screening
- Requirement for mechanical ventilation or ECMO at Screening
- Hypotension at Screening, defined as supine BP <95 mm Hg systolic or <55 mm Hg diastolic
- Severe liver injury defined as AST or ALT β₯5x the upper limit of normal
- Severe kidney failure defined as an estimated glomerular filtration rate (eGFR) <30 mL/min
- Any known immune deficiency
- Pregnancy or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Angiotensin (1-7) Angiotensin-(1-7) Participants receive treatment for 7 days. Placebo Placebo Participants receive treatment for 7 days.
- Primary Outcome Measures
Name Time Method Time to recovery Up to 29 days Time to recovery, defined as attaining a score of 6, 7, or 8 on the COVID-19 disease severity scale, an 8 point ordinal scale used in the NIH Adaptive COVID-19 Treatment Trial (ACTT; NCT04280705).
1. = Death;
2. = Hospitalized and on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
3. = Hospitalized and on non-invasive ventilation or high-flow oxygen devices;
4. = Hospitalized and requiring supplemental oxygen;
5. = Hospitalized and not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or otherwise);
6. = Hospitalized and not requiring supplemental oxygen and no longer requiring ongoing medical care;
7. = Not hospitalized, limitation on activities and/or requiring home oxygen;
8. = Not hospitalized, no limitation on activities
- Secondary Outcome Measures
Name Time Method Incidence of mortality at Day 29 29 days Number of participants requiring mechanical ventilation or ECMO, or dying, through Day 29 Up to 29 days COVID-19 disease severity scale score on Day 8 Day 8 COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
COVID-19 disease severity scale score on Day 15 Day 15 COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
COVID-19 disease severity scale score on Day 29 Day 29 COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Number of days alive and not on mechanical ventilator or ECMO in the 28 days following first dose Up to 29 days COVID-19 disease severity scale score on Day 22 Day 22 COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Trial Locations
- Locations (1)
Stanford University
πΊπΈStanford, California, United States